Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court lifts Medtronic’s RX catheter injunction

This article was originally published in The Gray Sheet

Executive Summary

A May 2000 injunction that has barred Medtronic from manufacturing or marketing rapid-exchange catheters will end Oct. 29, the date on which Abbott's RX patent was originally supposed to expire, the U.S. District Court for the Northern District of California 1ruled Oct. 21. The court concluded that Abbott would not suffer any material damage, and that lifting the ban suits the public interest and the spirit of the Patent Term Restoration Act. The ruling follows a one-year interim patent extension granted to Abbott on Oct. 14 by the U.S. Patent and Trademark Office (2"The Gray Sheet" Oct. 20, 2008, In Brief). Medtronic says it will announce its commercial plans after Oct. 29. The firm may choose to launch despite the extension and risk modest infringement damages if a full extension is granted, according to Morgan Stanley analyst David Lewis
Advertisement

Related Content

Abbott gains RX catheter patent extension
Advertisement
UsernamePublicRestriction

Register

MT026711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel